Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.

Yoshioka T, Shien K, Takeda T, Takahashi Y, Kurihara E, Ogoshi Y, Namba K, Torigoe H, Sato H, Tomida S, Yamamoto H, Soh J, Fujiwara T, Toyooka S.

Cancer Sci. 2019 Jun 4. doi: 10.1111/cas.14089. [Epub ahead of print]

2.

Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.

Kurihara E, Shien K, Torigoe H, Takeda T, Takahashi Y, Ogoshi Y, Yoshioka T, Namba K, Sato H, Suzawa K, Yamamoto H, Soh J, Okazaki M, Shien T, Tomida S, Toyooka S.

Anticancer Res. 2019 Apr;39(4):1767-1775. doi: 10.21873/anticanres.13283.

PMID:
30952716
3.

Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations.

Ogoshi Y, Shien K, Yoshioka T, Torigoe H, Sato H, Sakaguchi M, Tomida S, Namba K, Kurihara E, Takahashi Y, Suzawa K, Yamamoto H, Soh J, Toyooka S.

Oncol Lett. 2019 Mar;17(3):2729-2736. doi: 10.3892/ol.2019.9908. Epub 2019 Jan 8.

4.

Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma.

Namba K, Tomida S, Matsubara T, Takahashi Y, Kurihara E, Ogoshi Y, Yoshioka T, Takeda T, Torigoe H, Sato H, Shien K, Yamamoto H, Soh J, Tsukuda K, Toyooka S.

BMC Cancer. 2019 Feb 26;19(1):175. doi: 10.1186/s12885-019-5374-1.

5.

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells.

Namba K, Shien K, Takahashi Y, Torigoe H, Sato H, Yoshioka T, Takeda T, Kurihara E, Ogoshi Y, Yamamoto H, Soh J, Tomida S, Toyooka S.

Mol Cancer Res. 2019 Feb;17(2):499-507. doi: 10.1158/1541-7786.MCR-18-0628. Epub 2018 Nov 21.

PMID:
30463991
6.

Newly developed anti-S100A8/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis.

Kinoshita R, Sato H, Yamauchi A, Takahashi Y, Inoue Y, Sumardika IW, Chen Y, Tomonobu N, Araki K, Shien K, Tomida S, Torigoe H, Namba K, Kurihara E, Ogoshi Y, Murata H, Yamamoto KI, Futami J, Putranto EW, Ruma IMW, Yamamoto H, Soh J, Hibino T, Nishibori M, Kondo E, Toyooka S, Sakaguchi M.

Int J Cancer. 2019 Jul 15;145(2):569-575. doi: 10.1002/ijc.31982. Epub 2018 Dec 14.

PMID:
30414170
7.

exSSSRs (extracellular S100 soil sensor receptors)-Fc fusion proteins work as prominent decoys to S100A8/A9-induced lung tropic cancer metastasis.

Kinoshita R, Sato H, Yamauchi A, Takahashi Y, Inoue Y, Sumardika IW, Chen Y, Tomonobu N, Araki K, Shien K, Tomida S, Torigoe H, Namba K, Kurihara E, Ogoshi Y, Murata H, Yamamoto KI, Futami J, Putranto EW, Ruma IMW, Yamamoto H, Soh J, Hibino T, Nishibori M, Kondo E, Toyooka S, Sakaguchi M.

Int J Cancer. 2019 Jun 15;144(12):3138-3145. doi: 10.1002/ijc.31945. Epub 2018 Dec 4.

PMID:
30365872
8.

Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.

Iida T, Ubukata M, Mitani I, Nakagawa Y, Maeda K, Imai H, Ogoshi Y, Hotta T, Sakata S, Sano R, Morinaga H, Negoro T, Oshida S, Tanaka M, Inaba T.

Eur J Med Chem. 2018 Oct 5;158:832-852. doi: 10.1016/j.ejmech.2018.09.003.

PMID:
30248655
9.

Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis.

Takahashi Y, Shien K, Tomida S, Oda S, Matsubara T, Sato H, Suzawa K, Kurihara E, Ogoshi Y, Namba K, Yoshioka T, Torigoe H, Yamamoto H, Soh J, Toyooka S.

Cancer Sci. 2018 Nov;109(11):3634-3642. doi: 10.1111/cas.13797. Epub 2018 Oct 6.

10.

Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.

Sato H, Yamamoto H, Sakaguchi M, Shien K, Tomida S, Shien T, Ikeda H, Hatono M, Torigoe H, Namba K, Yoshioka T, Kurihara E, Ogoshi Y, Takahashi Y, Soh J, Toyooka S.

Cancer Sci. 2018 Oct;109(10):3183-3196. doi: 10.1111/cas.13763. Epub 2018 Sep 14.

11.

Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia.

Ogoshi Y, Matsui T, Mitani I, Yokota M, Terashita M, Motoda D, Ueyama K, Hotta T, Ito T, Hase Y, Fukui K, Deai K, Yoshiuchi H, Ito S, Abe H.

ACS Med Chem Lett. 2017 Nov 20;8(12):1320-1325. doi: 10.1021/acsmedchemlett.7b00404. eCollection 2017 Dec 14.

12.

Mu rhythm suppression during the imagination of observed action.

Ogoshi S, Ogoshi Y, Momose S, Takezawa T, Mitsuhashi Y.

Conf Proc IEEE Eng Med Biol Soc. 2013;2013:4310-3. doi: 10.1109/EMBC.2013.6610499.

PMID:
24110686
13.

Synthesis and SAR of 2-phenyl-1-sulfonylaminocyclopropane carboxylates as ADAMTS-5 (Aggrecanase-2) inhibitors.

Shiozaki M, Imai H, Maeda K, Miura T, Yasue K, Suma A, Yokota M, Ogoshi Y, Haas J, Fryer AM, Laird ER, Littmann NM, Andrews SW, Josey JA, Mimura T, Shinozaki Y, Yoshiuchi H, Inaba T.

Bioorg Med Chem Lett. 2009 Nov 1;19(21):6213-7. doi: 10.1016/j.bmcl.2009.08.093. Epub 2009 Sep 3.

PMID:
19767207
14.

Novel N-substituted 2-phenyl-1-sulfonylamino-cyclopropane carboxylates as selective ADAMTS-5 (Aggrecanase-2) inhibitors.

Shiozaki M, Maeda K, Miura T, Ogoshi Y, Haas J, Fryer AM, Laird ER, Littmann NM, Andrews SW, Josey JA, Mimura T, Shinozaki Y, Yoshiuchi H, Inaba T.

Bioorg Med Chem Lett. 2009 Mar 15;19(6):1575-80. doi: 10.1016/j.bmcl.2009.02.024. Epub 2009 Feb 11.

PMID:
19243944
15.

Importance of interaction between C1 domain and lipids in protein kinase C alpha activation: hydrophobic side chain direction in isobenzofuranone ligands controls enzyme activation level.

Hirai G, Shimizu T, Watanabe T, Ogoshi Y, Ohkubo M, Sodeoka M.

ChemMedChem. 2007 Jul;2(7):1006-9. No abstract available.

PMID:
17492704
16.
17.

Evaluation of series of isobenzofuranone dimers as PKCalpha ligands: implication for the distance between the two ligand binding sites.

Baba Y, Mayumi S, Hirai G, Kawasaki H, Ogoshi Y, Yanagisawa T, Hashimoto Y, Sodeoka M.

Bioorg Med Chem Lett. 2004 Jun 7;14(11):2969-72.

PMID:
15125970
18.

Design, synthesis, and structure-activity relationship of new isobenzofuranone ligands of protein kinase C.

Baba Y, Ogoshi Y, Hirai G, Yanagisawa T, Nagamatsu K, Mayumi S, Hashimoto Y, Sodeoka M.

Bioorg Med Chem Lett. 2004 Jun 7;14(11):2963-7.

PMID:
15125969
19.

[Solitary plasmacytoma of the thorax: report of two cases].

Hara F, Doihara H, Sato G, Hara K, Ogoshi Y.

Nihon Kyobu Geka Gakkai Zasshi. 1988 Nov;36(11):2516-20. Japanese. No abstract available.

PMID:
3209905
20.

[Evaluation of adjuvant Endoxan therapy in curative resected patients with stomach cancer].

Tsuda H, Ishiai S, Nakagawa J, Nishihara M, Takahashi S, Shiota K, Date M, Ogoshi Y, Naito M, Imai S, et al.

Nihon Gan Chiryo Gakkai Shi. 1985 Feb 20;20(1):114-21. Japanese. No abstract available.

PMID:
3998566

Supplemental Content

Loading ...
Support Center